Gabapentin

Phase 3Completed

0 views this week 0 watching⚡ Active

Interest: 40/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

Phase 3

Approved

Indication / Disease

Transient Insomnia

Conditions

Transient Insomnia

Trial Timeline

Aug 1, 2006 → Jan 1, 2007

NCT ID

NCT00659100

About Gabapentin

Gabapentin is a phase 3 stage product being developed by Pfizer for Transient Insomnia. The current trial status is completed. This product is registered under clinical trial identifier NCT00659100. Target conditions include Transient Insomnia.

What happened to similar drugs?

0 of 8 similar drugs in Transient Insomnia were approved

Approved (0) Terminated (0) Active (8)

🔄Gabapentin + Gabapentin + PlaceboPfizerPhase 3

🔄Gabapentin + PlaceboPfizerPhase 3

🔄Gabapentin + Gabapentin + PlaceboPfizerPhase 3

🔄Gabapentin + PlaceboPfizerPhase 3

🔄Milvexian + PlaceboBristol Myers SquibbPhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (10)

NCT ID	Phase	Status	Start	Completion	Indication
NCT01441401	Pre-clinical	Completed	Dec 1, 2011	Sep 1, 2014	Epilepsies, Partial
NCT00620555	Phase 3	Completed	May 1, 2008	Dec 1, 2010	Epilepsies, Partial
NCT00603473	Phase 3	Completed	Jan 1, 2008	Dec 1, 2009	Epilepsies, Partial
NCT00567268	Pre-clinical	Completed	Aug 1, 2007	May 1, 2014	Epilepsies, Partial
NCT00659100	Phase 3	Completed	Aug 1, 2006	Jan 1, 2007	Transient Insomnia
NCT00577967	Pre-clinical	UNKNOWN	Oct 1, 2005	Mar 1, 2006	Pruritus
NCT00533455	Phase 3	Terminated	Mar 1, 2004	Aug 1, 2007	Neuroleptic-Induced Tremor
NCT00137735	Phase 3	Completed	Oct 1, 2003	Dec 1, 2006	Carpal Tunnel Syndrome
NCT00644748	Approved	Completed	May 1, 2003	Aug 1, 2004	Diabetic Neuropathies
NCT00169013	Approved	Completed	May 1, 2002	Jun 1, 2006	Amputation of Lower Limb

Competing Products

10 competing products in Transient Insomnia

See all competitors

Product	Company	Stage	Hype Score
LY2624803 - Capsules + Zolpidem - Tablets + Placebo - Capsules + Placebo - Tablets	Eli Lilly	Phase 1	29
Gabapentin + Gabapentin + Placebo	Pfizer	Phase 3	40
Gabapentin + Gabapentin + Placebo	Pfizer	Phase 3	40
Gabapentin + Gabapentin + Placebo	Pfizer	Phase 3	40
Gabapentin + Placebo	Pfizer	Phase 3	40
Gabapentin + Gabapentin + Placebo	Pfizer	Phase 3	40
Gabapentin + Placebo	Pfizer	Phase 3	40
Milvexian + Placebo	Bristol Myers Squibb	Phase 3	47
Apixaban + Warfarin	Bristol Myers Squibb	Phase 3	40
Levosimendan + Placebo	Orion Corporation	Phase 2	32